PALISADE BIO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PALISADE BIO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $260.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $16.2K | Apr 2, 2018 |
| FY2015 | Dec 31, 2015 | $2.5K | Mar 14, 2016 |
| FY2015 | Sep 30, 2015 | $2.5K | Mar 14, 2016 |
| FY2015 | Jun 30, 2015 | $2.5K | Mar 14, 2016 |
| FY2015 | Mar 31, 2015 | $2.9K | Mar 14, 2016 |
| FY2015 | Dec 31, 2014 | $4.7K | Mar 14, 2016 |
| FY2015 | Sep 30, 2014 | $5.0K | Mar 14, 2016 |
| FY2015 | Jun 30, 2014 | $5.0K | Mar 14, 2016 |
| FY2015 | Mar 31, 2014 | $4.2K | Mar 14, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $250.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 26, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.78M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($14.44M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($12.30M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($14.26M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($26.62M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($10.32M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($8.35M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($4.92M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($15.67M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($21.07M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.06M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($14.86M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($13.07M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($15.72M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($41.85M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($9.30M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($8.63M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($8.26M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($13.31M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($20.64M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $16.00M | Mar 20, 2026 |
| FY2020 | Dec 31, 2020 | $2.02M | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | $4.06M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $3.96M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.10M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $13.16M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $12.64M | Mar 23, 2017 |
| FY2015 | Dec 31, 2014 | $8.36M | Mar 14, 2016 |
| FY2015 | Dec 31, 2013 | $7.29M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $6.11M | Mar 16, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $256.0K | Mar 15, 2013 |
| FY2012 | Dec 31, 2011 | $256.0K | Mar 15, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.85M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($12.19M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($11.13M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($13.36M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($14.77M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($4.77M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($7.26M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($7.69M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($13.42M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($15.62M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $4.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $10.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.0K | Mar 17, 2022 |
| FY2019 | Dec 31, 2018 | $1.7K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $11.4K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $98.1K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $176.3K | Mar 23, 2017 |
| FY2015 | Dec 31, 2014 | $207.9K | Mar 14, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.34M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $10.88M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $14.05M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $15.76M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $12.51M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.02M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $6.58M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $7.68M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $13.88M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $22.60M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.96M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.39M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $2.74M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.28M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $5.15M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $10.12M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.46M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.63M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.37M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $11.27M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.38M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $7.49M | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | $11.31M | Mar 20, 2026 |
| FY2024 | Dec 31, 2022 | $12.48M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $7.37M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($16.60M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($8.33M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $6.05M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $8.52M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $11.33M | Mar 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $135.90M | Mar 24, 2025 |
| FY2023 | Dec 31, 2023 | $121.50M | Mar 26, 2024 |
| FY2022 | Dec 31, 2022 | $109.20M | Mar 22, 2023 |
| FY2021 | Dec 31, 2021 | $94.60M | Mar 17, 2022 |
| FY2020 | Dec 31, 2020 | ($238.24M) | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | ($221.98M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($213.62M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($208.70M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($193.03M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($171.96M) | Mar 23, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.39M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $9.82M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $12.43M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $12.38M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $10.50M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $713.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $5.11M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.79M | Mar 27, 2020 |
| FY2019 | Dec 31, 2017 | $6.67M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $15.19M | Mar 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $87.0K | Mar 17, 2022 |
| FY2021 | Dec 31, 2020 | $1.14M | Mar 17, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (27) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (142) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (27) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (169) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 159.44M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 2.77M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 618,056 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 2.94M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 284,780 | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 2.77M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 3.87M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | 910,253 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 15.16M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 11.03M | Apr 2, 2018 |